摘要
目的:观察维格列汀对2型糖尿病(type 2 diabetes melitus,T2DM)患者尿8-羟基脱氧鸟苷(8-hydroxy-deoxyguanosine,8-OHd G)水平的影响,探讨其抗氧化应激作用及其防治糖尿病并发症的作用。方法:将82例血糖控制欠佳的T2DM患者以随机数字表法分为联合维格列汀治疗组(A组)和磺脲类药物治疗组(B组)各41例,治疗12周。观察2组患者治疗前后空腹血糖(FBG)、糖化血红蛋白(Hb A1c)、尿8-OHd G水平变化。结果:12周的治疗结束时,受试对象共75例,其中A组37例,B组38例(A组2例失访、2例血糖控制不达标退出;B组2例失访、1例血糖控制不达标退出)。治疗12周后,2组患者FBG、Hb A1c和尿8-OHd G水平均较治疗前明显下降(P<0.01);2组患者FBG、Hb A1c水平的差异无统计学意义(P>0.05),但2组患者尿8-OHd G水平的差异有统计学意义(P<0.05)。结论:维格列汀降低T2DM患者尿8-OHd G水平、减轻氧化应激可能是其防治糖尿病肾病等慢性并发症的机制之一。
OBJECTIVE：To evaluate the effect of vildagliptin on 8-hydroxy-deoxyguanosine （8-OHdG） in urine of patients with type 2 diabetes mellitus （ type 2 diabetes melitus.T2DM） and investigate its antioxidative stress effect and efficacy in the prevention and treatment of diabetic complications.METHODS：82 T2DM patients with poor blood glucose control were randomized to either combined vildagliptin treatment group （ group A ） or sulfonylurea drug treatment group （ group B ） for treatment of 12 weeks.Fasting blood glucose （ FBG ） , glycosylated hemoglobin （ HbA1c） and urinary 8-OHdG levels in the 2 groups were recorded before and after treatment.RESUTLS： After completion of 12-week treatment, among a total of 75 cases including 37 cases in group A and 38 cases in group B, 2 in group A and 2 in group B were lost to follow-up, and 2 in group A and 1 in group B were excluded because of failure to meet the target of blood glucose control.After 12 weeks of treatment, compared with before treatment, FBG, HbA1c and urinary 8-OHdG levels decreased significantly in both groups （P〈0.01）;the differences between the two groups in FBG, HbA1c levels were of no statistical significance （P〉0.05）, but the differences in urinary 8-OHdG levels have significant difference （ P〈0.05 ） .CONCLUSIONS： The action of vildagliptin to reduce urinary 8-OHdG level and attenuate oxidative stress in patients with T2DM may be one of the mechanisms underlying its efficacy in the prevention and treatment of diabetic nephropathy and other chronic complications.
出处
《中国医院用药评价与分析》
2015年第6期813-815,共3页
Evaluation and Analysis of Drug-use in Hospitals of China
